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Abstract
Erythropoietin (EPO) has been well characterized as a renal glycoprotein hormone regulating red blood cell production by inhibiting
apoptosis of erythrocyte progenitors in hematopoietic tissues. EPO exerts regulatory effects in cardiac and skeletal muscles.
Duchenne muscular dystrophy is a lethal degenerative disorder of skeletal and cardiac muscle. In this study, we tested the possible
therapeutic beneficial effect of recombinant EPO (rhEPO) in dystrophic muscles in mdx mice. Total strength was measured using a
force transducer coupled to a computer. Gene expression for myostatin, transforming growth factor-b1 (TGF-b1), and tumor
necrosis factor-a (TNF-a) was determined by quantitative real time polymerase chain reaction. Myostatin expression was
significantly decreased in quadriceps from mdx mice treated with rhEPO (rhEPO=0.60±0.11, control=1.07±0.11). On the other
hand, rhEPO had no significant effect on the expression of TGF-b1 (rhEPO=0.95±0.14, control=1.05±0.16) and TNF-a
(rhEPO=0.73±0.20, control=1.01±0.09). These results may help to clarify some of the direct actions of EPO on skeletal muscle.
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Introduction
Erythropoietin (EPO) has been well characterized as a
renal glycoprotein hormone regulating red blood cell
production by inhibiting apoptosis of erythrocyte progenitors
in hematopoietic tissues (1). EPO receptors have been
described in many different cells and tissues, including
muscle, neurons, astrocytes, microglia, developing heart,
cancer cell lines, Leydig cells, and gastric mucosal cells,
suggesting other actions of this hormone (2). Indeed, many
of these tissues are responsive to stimulation with recombi-
nant human EPO (rhEPO) (2). The relationship between
EPO receptors and skeletal muscle has been poorly
investigated. It has recently been reported that EPO exerts
regulatory effects on both cardiac and skeletal muscle (3).
Because mouse myoblasts express EPO receptors,
administration of EPO can stimulate proliferation of myo-
blasts to expand the progenitor population during differentia-
tion, resulting in a potential role in muscle development or
repair (4). Mice lacking EPO or its receptors suffer from
heart hypoplasia and have a reduced number of proliferating
cardiac myocytes (5).
The effects of EPO on muscle cells have also attracted
the attention of athletes. Because EPO increases red blood
cell mass and exercise capacity in anemic patients, it might
have the same effect in an athlete’s body, thereby
enhancing performance (6). In addition to the hematopoie-
tic effects, EPO is capable of promoting angiogenesis in
muscle cells (7), providing an additional route to increase
the supply of oxygen to the working muscles. Furthermore,
the possible involvement of EPO in muscle repair pro-
cesses (4) can imply that athletes who abuse rhEPO have
healthier muscles. With this reasoning, athletes began
using rhEPO, and thus rhEPO has been on the International
Olympic Committee’s list of banned substances since
1990 (6).
Duchenne muscular dystrophy (DMD) is a lethal
degenerative disorder of skeletal and cardiac muscles that
affects 1 in 3500 male births (8). DMD patients character-
istically display progressive muscle weakness, which begins
in early childhood (9). Although DMD is present at birth,
clinical symptoms are not evident until 3-5 years of age (10).
Initial symptoms include leg weakness and increasing
convex curvature of the spine muscles and results in
progressive weakness, usually leaving DMDpatients wheel-
chair bound by age 11 or 12 years (11).
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Affected individuals usually die due to respiratory or
cardiac insufficiency by the second or third decade of life
(12). So far, the only pharmacological treatment proven to
be effective for DMD is steroids (13).
Dystrophin is considered a key structural element in
muscle fiber, and the primary function of the dystrophin-
associated protein complex is to stabilize the plasma
membrane. The absence of dystrophin is followed by a
sequence of events such as calcium influx, reactive oxygen
species activity, and inflammation, leading to muscle injury
(14).
This study tested the possible beneficial effect of
recombinant EPO therapy in the degenerative process of
dystrophic muscles inmdxmice. The absence of dystrophin
in thesemice produces a phenotype quite different from that
of dystrophin deficiency in humans. Under normal condi-
tions, mdx mice show little overt symptoms of weakness,
but, if forced to engage, they show more pathological
changes than when resting (15).
Material and Methods
Male mdx mice were maintained in the experimental
laboratory of ABC Faculty of Medicine (FMABC) at constant
temperature (206C), with a 12:12-h light-dark cycle, and
received diet and water ad libitum. The mice weighed 25-
30 g. All procedures were conducted in accordancewith the
Declaration of Helsinki and the Guide for the Care and Use
of Laboratory Animals, and were approved by the Ethics
Committee of Faculdade de Medicina do ABC in 2006
(Protocol: #04/2006).
The experimental groups were as follows: 7 mdx mice
were injected with rhEPO (1000 IU/kg ip) 3 times per week
and 6 mdx mice received saline. All animals were
submitted to exercise on an electric treadmill (5 days/
week, 20 cm/s, 10 min).
Measurement of whole body strength
Whole body strength was measured weekly using a
force transducer coupled to a computer (15). The tail of
each mouse was connected through a nonflexible nylon
tube to the transducer so that they were electrically
stimulated to run, and the force required to pull the cable
was continuously recorded. The force values were normal-
ized to the weight of each animal.
Muscle preparation
After 12 weeks of treatment, a muscle biopsy was
carried out on all mdx mice. Samples were collected from
the left quadriceps, dissected, frozen in liquid nitrogen,
and stored at –806C. Total tissue RNA was extracted with
Trizol reagent (Invitrogen Co., USA), according to the
manufacturer’s instructions, quantified by absorbance at
260 nm, and stored in diethylpyrocarbonate-treated water
at –806C. The integrity of RNA was routinely verified by
agarose gel electrophoresis. Total RNA (2 mg) was used
for first-strand cDNA synthesis (reverse transcriptase)
using Moloney murine leukemia virus, and RNaseOUT
was also added to protect the RNA during this process).
Quantitative real time polymerase chain reaction
Gene expression of myostatin, transforming growth
factor-b1 (TGF-b1) and tumor necrosis factor-a (TNF-a)
was determined by quantitative real time polymerase
chain reaction (qRT-PCR) using SybrGreen Master Mix
(Invitrogen). b-actin was used as an internal control. The
reaction was carried out with 1 mL diluted cDNA (20 ng),
10 mL SybrGreen Master Mix (Invitrogen), 0.5 mL forward
primer (10 mM), 0.5 mL reverse primer (10 mM), and 8 mL
RNAse-free water in a final volume of 20 mL/well. The
thermocycle included an initial incubation at 956C for
2 min, followed by 40 cycles of 956C for 15 s, 606C for
60 s, and 726C for 15 s. The qRT-PCR was performed
in triplicate. The primer sequences and their respective
product length are reported in Table 1.
Relative gene expression fold change was calculated
using the delta delta Ct method. The results were
subjected to analysis of variance using the GBStat
program (England), and P,0.05 was considered to be
significant.
Results
Measurement of whole body strength
The muscle strength values were appropriate for the
weight of the animal. There was no change in strength
between the control animals and those treated with
rhEPO during the 12 weeks of treatment. The total force
of mdx mice is reported in Figure 1.
qRT-PCR
In order to determine whether recombinant EPO had
an effect on the regeneration process of mdx dystrophic
muscle in mice, we quantified expression of the myostatin
gene, TGF-b1, and TNF-a by qRT-PCR. After 12 weeks
of treatment with rhEPO, there was a significant decrease
in myostatin gene expression (Figure 2). There was no
difference in TGF-b1 and TNF-a gene expression between
groups.
Discussion
This study evaluated the possible beneficial effect of
recombinant EPO therapy in the degenerative process
of dystrophic muscles in mdx mice, the most common
experimental model used to study DMD (15). We observed
no change in strength between the control animals and
those treated with rhEPO during the 12 weeks of treatment.
Myostatin expression was significantly decreased in quad-
riceps from mdx mice treated with rhEPO; however, no
significant effect of rhEPO was seen in the expression of
TGF-b1 and TNF-a.
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DMD is the most common lethal genetic disease.
Corticosteroids are currently the only available disease-
modifying therapy for DMD, by prolonging independent
ambulation and delaying the onset of secondary complica-
tions (16). However, the use of chronic high-dose cortico-
steroids for DMD is frequently associated with significant
side effects and does not stop disease progression (16). An
effective treatment for DMD requires a combination of
therapies, including pharmacological agents, gene therapy,
and target cells in an attempt to reach the process pathways
involved in muscle degeneration and necrosis (17). EPO
has several effects that could aid in the repair of skeletal
muscle injury and prevention of fibrosis (1). In mdxmice, we
did not observe any increase in muscle strength. An EPO
analog, carbamylated EPO, was not demonstrated as an
effective therapy for DMD in mdx mice (18).
We assessed the gene expression of cytokines involved
in the disease and observed a direct action of the drug in
spite of increased muscle oxygen delivery in vitro.
TGF-b1 is highly upregulated in dystrophic skeletal
muscle (19), and the level of TGF-b1 protein is significantly
elevated in the mdx diaphragm at 12 weeks of age (20).
These cytokines are expressed by inflammatory cells such
as macrophages (21) and have been shown to stimulate
collagen synthesis (22). In our experiments, the results of
TGF-b1 did not show any difference. Perhaps the EPO
concentration we usedwas not able to activate this pathway.
DMD patients have higher serum TNF-a levels, and
TNF-a-positive fibers have been found by in situ hybridiza-
tion and immunohistochemistry in muscles of dystrophic
DMD subjects (23). Controversial results and muscle type
dependent effects have been observed in TNF-a knockout
mdx mice; and histopathological analysis has found that the
absence of TNF-a in vivo resulted in equivocal findings as
opposed to amelioration of muscle pathology as predicted
(24), although long-term deletion of TNF-a appeared
beneficial in older (12 months) mdx/TNF-a(–/–) mice (25).
The pharmacological approach using weekly TNF-a anti-
body during early postnatal life clearly delayed and greatly
reduced the breakdown of dystrophicmuscle (26). However,
no proof of functional benefit of this specific anti-TNF-a
therapy has been provided. We did not observe a significant
effect of EPO in expression of the TGF gene.
Myostatin, a member of the TGF family, is an important
negative regulator of skeletal muscle mass (27). The
deletion of the myostatin gene in the mdx mouse increases
not only muscle mass but also muscle strength (as
measured by grip strength). Remarkably, histological
analysis of the diaphragm, one of the most severely affected
muscles in the mdx mouse, showed a reduced dystrophic
phenotype in myostatin/mdx double mutants (28). The
injection of anti-myostatin monoclonal antibodies into mdx
mice on a weekly basis for a period of 3 months resulted in
muscle mass increases up to 35% in individual muscles
after myostatin blockade (29). Conversely, transgenic mice
that overexpress myostatin selectively in skeletal muscle
have lower muscle mass (30). Finally, these observations
indicate that myostatin negatively regulates skeletal muscle
mass. For the first time, we report that a significant reduction
in myostatin expression in mdx mice treated with rhEPO
may signify a new direct mode of action of EPO in skeletal
muscle.
The direct actions of EPO in skeletal muscles indepen-
dent of its action in the hematopoietic system have been
Figure 1. Strength of the entire body of mdx mice treated with
recombinant human erythropoietin (rhEPO) or saline (control) for
12 weeks. P.0.05, GBStat test.
Table 1. Forward and reverse primers for quantitative real time PCR analyses.
Primer Sequence Product length (pb)
TGF-b1 (accession No. M13177) 80
Forward 59 CCCCACTGATACGCCTGAGT 39
Reverse 59 AGCCCTGTATTCCGTCTCCTT 39
TNF-a (accession No. NM_013693.2) 275
Forward 59 ATGAGCACAGAAAGCATGATC 39
Reverse 59 TACAGGCTTGTCACTCGAATT 39
Myostatin (accession No. NM_010834.2) 83
Forward 59 ACGCTACCACGGAAACAATC 39
Reverse 59 AAAGCAACATTTGGGCTTTC 39
TGF-b1: transforming growth factor beta 1; TNF-a: tumor necrosis factor alpha.
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studied by several authors (31,32). EPO has been
described as exerting effects similar to vascular endothelial
growth factor (VEGF) on the angiogenic process, and one
of the mechanisms by which EPO appears to promote
angiogenesis is by enhancing the level of VEGF in tissues.
A close association between VEGF and EPO in angiogen-
esis has been proposed (33), and EPO treatment has been
found to enhance the release of VEGF from marrow
stromal cells (31) and to increase levels of VEGF in brain
(32). Considering the importance of VEGF in skeletal
muscle capillary growth (34), it is, therefore, plausible that
one of the angiogenic effects of EPO is mediated by
promoting VEGF levels in muscle. This effect can explain
the decrease in myostatin in our experiments.
Human myoblasts treated with bupivacaine showed a
dose-dependent decrease in mitochondrial membrane
potential associated with unusual morphologies.
Impairment of mitochondrial bioenergetics was prevented
partially by the use of rhEPO co-administered with
bupivacaine (35).
Another interesting potential physiological role of EPO
in skeletal muscle is in muscle fiber growth. Erythropoietin
receptor (EPO-R) activation stimulates the signal transdu-
cer and activator of transcription 5 (STAT5), which is
known tomodulate cell proliferation and differentiation (36).
STAT5 also activates the phosphoinositide 3 (PI3)-kinase-
protein kinase B (Akt) signaling pathway (37,38), which is
believed to result in activation of AKT and p70s6K, which in
turn plays a role in transcription and cell cycle progression.
This pathway has been suggested to be critical in the
regulation of skeletal muscle hypertrophy (38), On the
basis of the above findings, it appears plausible that EPO-
R activation may contribute to the regulation of skeletal
muscle fiber growth, activating the STAT pathway and
downregulating myostatin, as shown in our results.
We can speculate that EPO regulates the expression of
various genes. Acute injections of rhEPO (15,000 IU) did not
change mRNA levels of VEGF, hypoxia-inducible factor 1a
(HIF-1a), insulin-like growth factor, ferroportin, myogenic
differentiation 1 (MyoD), and myogen in biopsies obtained 2,
4, 6, and 10 h after injection of rhEPO, while small
inductions of myoglobin, EPO-R, transferrin receptor, and
myogenic regulatory factor (MRF4) were observed (39).
In our study, the control group was mdx mice treated
with saline, because we wanted to observe the possible
beneficial effects of recombinant EPO therapy in the
degenerative process of dystrophic muscles. We adopted
the same experimental model with mdx mice, as had been
reported in a previous study from our group (40).
Studying the muscles of mice with muscular dystro-
phy, we observed no increase in muscle strength, but we
found a significant reduction in myostatin. This result can
help to clarify some of the mechanisms of the direct action
of EPO on skeletal muscle.
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